

	Indication	Therapeutic Area	Sponsor	Product	CRO	Phase	Lead Coordinator	Clinical Description	Study Status
	Attention Deficit Hyperactivity Disorder (ADHD)	Child & Adolescent Psychiatry	Shire Development LLC	SP0489-347	Pfizer, Inc.	I		ADHD in Children Ages 4-5 years	
	Attention Deficit Hyperactivity Disorder (ADHD)	Child & Adolescent Psychiatry	Shire Development LLC	SP0489-348	Novartis Pharmaceuticals Corporation	II		Adult and Pediatric ADHD in Children and Adolescents	
	Attention Deficit Hyperactivity Disorder (ADHD)	Child & Adolescent Psychiatry	Supernus Pharmaceuticals, Inc.	RJ2902	SGS Life Science - Clinical Research	III		Evaluation of SPN 821 in 200 and 400 mg Efficacy and Safety in Adults	
	Major Depressive Disorder	Child & Adolescent Psychiatry	Forest Research Institute	VLM-MD-31		II		Placebo-controlled study in Major Depressive Disorder	
	Major Depressive Disorder	Neurology	Akadia Pharmaceuticals, Inc.	VLM-SO-042		II		Placebo-controlled study in Schizophrenia	
	Major Depressive Disorder - Pediatric	Child & Adolescent Psychiatry	Forest Research Institute	VLM-MD-32		II		Major Depressive Disorder	
	Schizophrenia	Teva	Neuroscience Division	TRV0603-CNS-0072	ICON	II		Schizophrenia	
	Tourette's Disorder	Child & Adolescent Psychiatry	Neuroline Therapeutics	NBI-0884-TSD003		II		Treatment of Pediatric Subjects with Tourette Syndrome	
	Tourette's Disorder	Neurology	Novartis Pharmaceuticals Corporation	TS-004-003		II		Tourette Syndrome in Children and Adolescents	
	Tourette's Disorder	Child & Adolescent Psychiatry	Novartis Pharmaceuticals Corporation	TS07077-CNS-30000		II		Tourette Syndrome in Children and Adolescents	
	Agitation in Dementia	Adult Psychiatry	Akadia Pharmaceuticals, Inc.	ACQ-103-046	Worldwide Clinical Trials	II		Adult and Elderly Subjects With Neurodegenerative Disorders Related to Neuroendocrine System	
	Agitation in Dementia	Adult Psychiatry	Akadia Pharmaceuticals, Inc.	ACQ-103-047	Worldwide Clinical Trials	II		Adult and Elderly Subjects With Neurodegenerative Disorders Related to Neuroendocrine System	
	Borderline Personality Disorder	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-0042	Synapse Health, LLC	I		Borderline Personality Disorder	
	Adrenal Pheo PFO	Psychiatry	H. Lundbeck A/S	1356A4		II		Major Depressive Disorder	
	Adrenal Pheo PFO	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-0019	Synapse Health, LLC	I		Borderline Personality Disorder	
	Adrenal Pheo PFO	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	400-201-0006	Synapse Health, LLC	I		Borderline Personality Disorder	
	Alzheimer's Disease	Adult Psychiatry	AZTHERAPY, INC.	ATZ-001		II		Efficacy study of AZTERTINIB in subjects with evidence of early Alzheimer's d	
	Alzheimer's Disease	Neurology	Neurim Pharmaceuticals Ltd.	NEP-011-400	MDC Pharma	I		Alzheimer's Disease	
	Alzheimer's Disease	Adult Psychiatry	Otsuka Pharma Dev. & Com. Inc.	331-14-2143	INC Research	I		Alzheimer's Disease	
	Alzheimer's Disease	Adult Psychiatry	Teva Neuroscience	TS-004	Parade International LLC	I		SUBJECTS WITH MODERATE ALZHEIMER'S DISEASE	
	Alzheimer's Disease	Future Studies	Teva Neuroscience Partners	NPMT076-CNS-201		I		Early Stage Alzheimer's Disease	
	Alzheimer's Disease	Neurology	Alkermes, Inc.	ATH-1017-A01-003	Worldwide Clinical Trials	I		Mild to Moderate Alzheimer's	
	Alzheimer's Disease	Neurology	Alkermes, Inc.	ATH-1017-A01-003	Worldwide Clinical Trials	I		Mild to Moderate Alzheimer's	
	Alzheimer's Disease	Neurology	Asana Pharmaceuticals, Inc.	15-AOP-786-301		II		Treatment of Agitation in Patients With Dementia Of the Alzheimer's Type	
	Alzheimer's Disease	Neurology	Asana Pharmaceuticals, Inc.	ASU-2-3-AOP-786-301		II		Treatment of Agitation in Patients with Dementia of the Alzheimer's Type	
	Alzheimer's Disease	Neurology	Asana Pharmaceuticals, Inc.	ASU-2-3-AOP-786-301		II		Treatment of agitation associated with dementia of the Alzheimer's type	
	Alzheimer's Disease	Neurology	Assure Therapeutics, Inc.	ASU-55-A0-301	Assure Therapeutics	I		Neurologically Administered for Treatment in Subjects with Mild Alzheimer's Disease	
	Alzheimer's Disease	Neurology	EDP Pharma, LLC	NEC13-1746-301		I		Mild Cognitive Impairment due to Alzheimer's Disease - Phase Iib	
	Alzheimer's Disease	Neurology	NuroRx, Inc.	NV01-41	Premier Research International, LLC	II		Mild Cognitive Impairment due to Alzheimer's Disease - Phase Iib	
	Alzheimer's Disease	Neurology	TID Therapeutics, Inc.	TID009-002		I		Phase I, Double Blind, Placebo-Controlled, Multi-Center Study to Evaluate	
	Pediatric Generalized Anxiety Disorder	Child & Adolescent Psychiatry	Allegion Sales, LLC	ALM-002-60	Synapse Health, LLC	I		Pediatric Generalized Anxiety Disorder	
	Anxiety	Neurology	Otsuka Pharma Dev. & Com. Inc.	BW4155-31	Synapse Health, LLC	I		A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Tricyclic Antidepressant, 52 Week Treatment of Depression in Adults with ADHD	
	Attention Deficit Hyperactivity Disorder (ADHD)	Adult Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-0013	Synapse Health, LLC	I		Adult Attention-deficit/hyperactivity Disorder (ADHD)	
	Attention Deficit Hyperactivity Disorder (ADHD)	Child & Adolescent Psychiatry	Supernus Pharmaceuticals, Inc.	RJ2902	SGS Life Science - Clinical Research	II		Evaluation of SPN 821 in 200 and 400 mg Efficacy and Safety in Children with ADHD	
	Attention Deficit Hyperactivity Disorder (ADHD)	Child & Adolescent Psychiatry	Supernus Pharmaceuticals, Inc.	RJ2902	SGS Life Science - Clinical Research	II		Adult Attention-deficit/hyperactivity Disorder (ADHD)	
	Attention Deficit Hyperactivity Disorder (ADHD)	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-0016	Synapse Health, LLC	I		Adult Attention-deficit/hyperactivity Disorder (ADHD)	
	Attention Deficit Hyperactivity Disorder (ADHD)	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-0017	Synapse Health, LLC	I		Treatment of Children With Attention-deficit/hyperactivity Disorder	
	Attention Deficit Hyperactivity Disorder (ADHD)	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-0018	Synapse Health, LLC	I		Adult Attention Spectrum Disorder	
	Attention Deficit Hyperactivity Disorder (ADHD)	Neurology	Supernus Pharmaceuticals, Inc.	RJ2902	Synapse Health, LLC	I		Adult Attention Spectrum Disorder	
	Attention Deficit Hyperactivity Disorder (ADHD)	Neurology	Supernus Pharmaceuticals, Inc.	RJ2902	Synapse Health, LLC	I		Adult Attention Spectrum Disorder	
	Behavioral Agitation in Autism	Neurology	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-0048	Synapse Health, LLC	I		Adult Attention Spectrum Disorder	
	Behavioral Agitation in Autism	Neurology	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-0048	Synapse Health, LLC	I		Adult Attention Spectrum Disorder	
	Back Pain	Pain Management / Anesthesiology	Neuroscience Pharmaceuticals	CIN-18	Worldwide Clinical Trials	II		Pain Due to Acute Back Muscle Spasms	
	Binge Eating Disorder (BED)	Psychiatry	Sunovion Pharmaceuticals Inc.	SPR930-322	INC Research	II		Binge Eating	
	Binge Eating Disorder (BED)	Psychiatry	Sunovion Pharmaceuticals Inc.	SPR930-322	Worldwide Clinical Trials	II		Binge Eating Disorder (BED) - Phase II	
	Binge Eating Disorder (BED)	Psychiatry	Sunovion Pharmaceuticals Inc.	SPR930-322	Worldwide Clinical Trials	II		Binge Eating Disorder	
	Bipolar Depression	Psychiatry	Intra-Cellular Therapies, Inc. (ITC)	ITC-007-002	Quintiles	II		Monotherapy Treatment of MDD Patients w/ Bipolar Disorder	
	Bipolar Depression	Psychiatry	Intra-Cellular Therapies, Inc. (ITC)	ITC-007-002	Quintiles	II		Adjunctive Therapy for Treating MDD Episodes w/ Bipolar Disorder	
	Complex Regional Pain Syndrome type 1 (CRPS-1)	Pain Management / Anesthesiology	Grünenthal	GR7013-04	Synapse Health, LLC	II		Complex Regional Pain Syndrome (CRPS)	
	Dementia	Neurology	Assure Therapeutics, Inc.	ASU-55-A0-301		I		Neurologically Administered for Treatment in Subjects with Mild Alzheimer's Disease	
	Depression	Neurology	Assure Therapeutics, Inc.	ASU-55-A0-302		II		Dementia Type of Alzheimer's - Phase II	
	Depression	Psychiatry	Forest Research Institute	NM-1942-006	Actavis	II		Evaluation of the Safety and Efficacy of Levomepromazine in AD Adolescent P	
	Depression	Psychiatry	Merck & Co.	NM-1942-006		II		Treatment Resistant Depression (TRD)	
	Depression	Psychiatry	No Sponsor	NM-1942-006		II		Assessing Phenotype, Risk Factors and Biomarkers in Adults 18 and over with	
	Depression	Psychiatry	Sage Therapeutics, Inc.	2112-PRP-201	Premier Research	II		Familial with Perinatal Depression Disorder	
	Fibromyalgia	Musculoskeletal	Sirtex Pharmaceuticals, Inc.	SP-624-201		I		A Multicenter, Double-Blind, Placebo-Controlled Study of the Sa	
	Major Depressive Disorder	Adult Psychiatry	Allegion Sales, LLC	ALM-001-001	Worldwide Clinical Trials	I		A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy	
	Major Depressive Disorder	Adult Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-0003	Synapse Health, LLC	I		Adult Attention-deficit/hyperactivity Disorder (ADHD)	
	Major Depressive Disorder	Child & Adolescent Psychiatry	H. Lundbeck A/S	13701A	ICON	II		Major Depressive Disorder	
	Major Depressive Disorder	Neurology	Allegion Sales, LLC	RAP-MD-04		II		Real-time Safety Study of MDD	
	Major Depressive Disorder	Neurology	Allegion Sales, LLC	RAP-MD-06		II		Study of Rapastinel as Adjunctive Therapy in MDD	
	Major Depressive Disorder	Neurology	Allegion Sales, LLC	RAP-MD-02		II		Rapastinel as Adjunctive Therapy in Major Depressive Disorder	
	Major Depressive Disorder	Neurology	Allegion Sales, LLC	RAP-MD-03		II		Major Depressive Disorder	
	Major Depressive Disorder	Neurology	Intra-Cellular Therapies, Inc. (ITC)	ITC-007-005	IQVIA INC.	II		Major Depressive Disorder	
	Major Depressive Disorder	Psychiatry	Blackthorn Therapeutics, Inc.	BT-002-002	Worldwide Clinical Trials	I		Major Depressive Disorder	
	Major Depressive Disorder	Neurology	Clevo Biosciences Limited	CLE002-MDD-202	Medalliance Pharmaceuticals, LLC	II		Major Depressive Disorder	
	Major Depressive Disorder	Psychiatry	Clevo Biosciences Limited	CLE002-MDD-202	Worldwide Clinical Trials	II		Major Depressive Disorder Patients with Inadequate Response to Standard Ant	
	Major Depressive Disorder	Psychiatry	Janzen & B.O.	076040030003		II		Major Depressive Disorder	
	Major Depressive Disorder	Psychiatry	Janzen & B.O.	07619640030003		II		Major Depressive Disorder	
	Major Depressive Disorder	Psychiatry	Neuroma Therapeutics, Inc.	NMMA-13340-301		II		MDD	
Major Depressive Disorder	Psychiatry	Neuroma Therapeutics, Inc.	NMMA-13340-301		II		Major Depressive Disorder		
	Major Depressive Disorder	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	400-201-0003	Synapse Health, LLC	I		Major Depressive Disorder	
	Major Depressive Disorder	Psychiatry	Retelma Therapeutics, Inc.	RE-101-001-001		II		Major Depressive Disorder	
	Major Depressive Disorder	Psychiatry	Takeda	LAU21004_402	Quintiles	IV		A Randomized, Double-Blind, Placebo-Controlled, Phase 4 Relapse Prevention	
	Major Depressive Disorder - Pediatric	Child & Adolescent Psychiatry	Xenon Pharmaceuticals	XPR-008-204	Midphase	II		Major Depressive Disorder	
	Major Depressive Disorder	Child & Adolescent Psychiatry	H. Lundbeck A/S	13701A	ICON	II		Pediatric patients aged 7 to 11 years, with Major Depressive Disorder	
	Major Depressive Disorder - Pediatric	Psychiatry	H. Lundbeck A/S	1356A4	ICON	II		Major Depressive Disorder	
	Migraine Headaches	Neurology	Seltro Pharmaceuticals, Inc.	STN002-002		II		Acute Treatment of Migraines	
	Obsessive Compulsive Disorder (OCD)	Neurology	Boehringer	BW4157-209	Cognitive Research Corporation	II		A Randomized, double-blind, placebo-controlled trial of adjunctive trinitrol	
	Obsessive Compulsive Disorder (OCD)	Neurology	Boehringer	BW4157-209	Cognitive Research Corporation	II		Obsessive Compulsive Disorder	
	Post Partum Depression	Adult Psychiatry	Sage Therapeutics, Inc.	2112-PRP-301	Synapse Health, LLC	II		Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy	
Post Partum Depression	Psychiatry	Reuron Neuroscience	RES20-201-PRP	Worldwide Clinical Trials	I		Patients with Postpartum Depression		
	Post Partum Depression	Psychiatry	Sage Therapeutics, Inc.	2112-PRP-404	Synapse Health, LLC	I		Postpartum Depression	
	Psychosis	Psychiatry	Akadia Pharmaceuticals, Inc.	ACQ-103-045	Worldwide Clinical Trials	II		Psychosis - Dementia Related	
	PTSD	Post-Traumatic Stress Disorder	Adimex	NYX-788-2004	Pfizer	II		Daily Doses of NYX-788 in Subjects with Post-Traumatic Stress Disorder	
	PTSD	Post-Traumatic Stress Disorder	Jazz Pharmaceuticals, Inc.	JZP50-201	ICON	I		Post-Traumatic Stress Disorder	
	PTSD	Psychiatry	Adimex	NYX-788-2009	Worldwide Clinical Trials	II		Post-Traumatic Stress Disorder	
	Schizophrenia	Child & Adolescent Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-0007	Synapse Health, LLC	I		Respiratory as Comorbidity: Therapy with Lorazepam in Treatment of Adults	
	Schizophrenia	Adult Psychiatry	Boehringer Ingelheim	800-440-201		I		Schizophrenia	
	Schizophrenia	Child & Adolescent Psychiatry	Allegion Sales, LLC	LVM-MD-14		II		Schizophrenia	
	Schizophrenia	Child & Adolescent Psychiatry	Otsuka Pharma Dev. & Com. Inc.	331-10-234	INC Research	II		Schizophrenia	
	Schizophrenia	Child & Adolescent Psychiatry	Otsuka Pharma Dev. & Com. Inc.	331-10-234	INC Research	II		Schizophrenia	
Schizophrenia	Psychiatry	Kanva Therapeutics, Inc.	KAN-011		II		Schizophrenia		
	Schizophrenia	Neurology	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-0005		II		Phase III Multi-Center, Open-label, Randomized, Placebo-controlled Study in Adult Subjects	
	Schizophrenia	Neurology	Teva Branded Pharmaceuticals Research R&D, Inc.	TRV0603-CNS-30078	ICON	II		Efficacy Study of Safety, Tolerability, and Efficacy of Risperidone Extended-Release	
	Schizophrenia	Psychiatry	Corcept Therapeutics	CVX-232-001	PPD Investigative Services, LLC	I		Adult Patients with Schizophrenia	
	Schizophrenia	Psychiatry	Corcept Therapeutics, Inc.	CVX-232-001	PPD Investigative Services, LLC	I		Adult Patients with Schizophrenia	
	Schizophrenia	Psychiatry	Kanva Therapeutics, Inc.	KAN-011	IQVIA INC.	II		Obsessive Adults with Schizophrenia Taking Antipsychotic Medications	
	Schizophrenia	Psychiatry	Kanva Therapeutics, Inc.	KAN-011	IQVIA INC.	II		Inadequately Controlled Symptoms of Schizophrenia	
	Schizophrenia	Psychiatry	Recaphy Life Sciences, Inc.	CRJ-01-02	Worldwide Clinical Trials	I		Schizophrenia (SLE)	
	Schizophrenia	Psychiatry	EngagePharm, Inc.	EPK-002-001	Worldwide Clinical Trials	I		Cognitive Impairment Associated with Schizophrenia (CAG)	
	Social Anxiety Disorder	Psychiatry	Tourette's Disorder	331-14-2144	Synapse Health, LLC	I		Tourette's Disorder	
	Social Anxiety Disorder	Psychiatry	Tourette's Disorder	331-14-2144	Synapse Health, LLC	I		Canadian Oral Solution in Subjects with Social Anxiety Disorder	